Georgetown Doc Works Toward Personalized Cancer Care | WAMU 88.5 - American University Radio

WAMU 88.5 : Metro Connection

Filed Under:

Georgetown Doc Works Toward Personalized Cancer Care

Play associated audio
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology
Jonathan Wilson
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology

About seven years ago, the laboratory run by Dr. Richard Schlegel at Georgetown University's Department of Pathology developed the technology for the first vaccine for Human Papillomavirus or HPV — a virus that can lead to cervical cancer. Now Dr. Schlegel's lab appears to have made another big discovery — one that could eventually change the way doctors treat all kinds of cancer. Metro Connection's Jonathan Wilson talked with doctor in his office at Georgetown University to find out what the lab's latest breakthrough medical trial revealed.

Dr. Schlegel explaining the concept of reprogrammed cells: "The finding that we have come upon, is that we have a way to grow normal and tumor cells from a patient very rapidly and very efficiently, which hasn't been able to be accomplished before. What it allows us to be able to do now is to go in and take a biopsy of someone's tumor, with a needle, for example, like a breast tumor if you had a biopsy, and within days have tumor cells growing out of there and normal cells if you have a normal area. So you can identify drugs that kill the tumor cells, and not the normal cells."

On how it could change cancer treatments: "You may have a drug that's known, to say, treat a lung tumor, in most cases, you'll get a response, but they [the tumors] come back. And then it becomes a game of oncology experimentation. I hate to say that, but you know, you don't know what's going to work, but you try another drug on the patient. And if it works, good, if it doesn't you move on to another one. The bad thing about that is every time you use a new drug on a patient, there's a lot of toxicity associated with it. So with each different round of chemotherapy, the patient gets sicker and sicker. So what we're able to do with this, we hope — when it gets tested in much larger trials — is to use the laboratory to define the spectrum of drugs that would be good to use on the patient and avoid all of the toxicities. We are not just going to take a drug off the shelf - drug 'x' is best for this population of patients who have lung tumors. We will actually take your tumor, and find out what drug is best for you. That's the ultimate goal."

Dr. Schlegel and his researchers caution that it could be years before validation studies on their work is completed, and government approval is granted for broader use of the new technique.


[Music: "House MD Theme" by Massive Attack from House MD Original Television Soundtrack]

NPR

Sarah Koenig On Serial: 'I Think Something Went Wrong With This Case'

Serial, the hugely popular (and sometimes controversial) podcast spun off from This American Life, wraps up its first season today. Audie Cornish speaks with Serial creator Sarah Koenig.
NPR

What The Change In U.S.-Cuba Relations Might Mean For Food

The decision to normalize relations is driving all kinds of speculation about American food companies opening up shop in Cuba. But analysts say: Don't expect to see McDonald's there anytime soon.
NPR

In List Of Changes For Secret Service, A New Fence Comes First

In independent review panel calls for changes ranging from a better fence at the White House to a new approach to training and leadership within the Secret Service.
NPR

White House Says Any Response To Sony Attack Needs To Be 'Proportional'

The White House won't confirm North Korea is behind the attack, citing an ongoing investigation. Nevertheless, it is mulling over its options.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.